New agents for acute myeloid leukemia: is it time for targeted therapies?

Bibliography

• Ferrara F. Unanswered questions in acute myeloid leukemia. Lancet Oncol 2004;5:443-50
   PubMed Web of Science ®Google Scholar
• Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol 2009;37:649-58
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Hematol Oncol Clin North Am 2010;24:35-63
   PubMed Web of Science ®Google Scholar
• Thomas X. Chemotherapy of acute leukemias in adults. Expert Opin Pharmacother 2009;10:221-37
   PubMed Web of Science ®Google Scholar
• Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011;29:487-94
   PubMed Web of Science ®Google Scholar
• Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011;29:475-86
   PubMed Web of Science ®Google Scholar
• Kumar CH. Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer 2011;2:95-107
   PubMedGoogle Scholar
• Robak T, Szmigielska-Kapłon A, Pluta A, Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity. Curr Med Chem 2011;18:638-66
   PubMed Web of Science ®Google Scholar
• Rockova V, Abbas S, Wouters BJ, Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood 2011;118:1069-76
   PubMed Web of Science ®Google Scholar
• Foran JM. New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematol Am Soc Hematol Educ Program 2010;2010:47-55
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354-65
   PubMed Web of Science ®Google Scholar
• Ferrara F, Palmieri S, Leoni F. Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol 2008;66:181-93
   PubMed Web of Science ®Google Scholar
• de The H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010;10:775-83
   PubMed Web of Science ®Google Scholar
• Ferrara F. Acute promyelocytic leukemia: what are the treatment options? Expert Opin Pharmacother 2010;11:587-96
   PubMed Web of Science ®Google Scholar
• Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 2011;29:495-503
   PubMed Web of Science ®Google Scholar
• Tallman M, Douer D, Gore S, Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy. Clin Lymphoma Myeloma Leuk 2010;10(Suppl 3):S122-6
   PubMedGoogle Scholar
• Estey E. High cytogenetic or molecular genetic risk acute myeloid leukemia. Hematol Am Soc Hematol Educ Program 2010;2010:474-80
   PubMedGoogle Scholar
• Gregory TK, Wald D, Chen Y, Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol 2009;2:23
   PubMed Web of Science ®Google Scholar
• Bacher U, Schnittger S, Haferlach T. Molecular genetics in acute myeloid leukemia. Curr Opin Oncol 2010;22:646-55
   PubMed Web of Science ®Google Scholar
• Falini B, Sportoletti P, Martelli MP. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol 2009;21:573-81
   PubMed Web of Science ®Google Scholar
• Falini B, Martelli MP, Bolli N, Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 2011;117:1109-20
   PubMed Web of Science ®Google Scholar
• Fernandez HF. New trends in the standard of care for initial therapy of acute myeloid leukemia. Hematol Am Soc Hematol Educ Program 2010;2010:56-
   PubMed Web of Science ®Google Scholar
• Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154-63
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Dohner K, Kneba M, Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009;94:54-60
   PubMed Web of Science ®Google Scholar
• Mrozek K, Marcucci G, Paschka P, Bloomfield CD. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol 2008;20:711-18
   PubMed Web of Science ®Google Scholar
• Solis EC. Treatment strategies in patients with core-binding factor acute myeloid leukemia. Curr Oncol Rep 2011;13:359-60
   PubMedGoogle Scholar
• Paschka P. Core binding factor acute myeloid leukemia. Semin Oncol 2008;35:410-17
   PubMed Web of Science ®Google Scholar
• Goyama S, Mulloy JC. Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects. Int J Hematol 2011;94:126-33
   PubMed Web of Science ®Google Scholar
• Sritana N, Auewarakul CU. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups. Exp Mol Pathol 2008;85:227-31
   PubMed Web of Science ®Google Scholar
• Cairoli R, Beghini A, Grillo G, Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006;107:3463-8
   PubMed Web of Science ®Google Scholar
• Park SH, Chi HS, Min SK, Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep 2009;4:77-82
   PubMedGoogle Scholar
• Luck SC, Russ AC, Du J, KIT mutations confer a distinct gene expression signature in core binding factor leukaemia. Br J Haematol 2010;148:925-37
   PubMed Web of Science ®Google Scholar
• Linnekin D. Early signaling pathways activated by c-kit in hematopoietic cells. Int J Biochem Cell Biol 1999;31:1053-74
   PubMed Web of Science ®Google Scholar
• Wang YY, Zhao LJ, Wu CF, C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 2011;108:2450-5
   PubMed Web of Science ®Google Scholar
• Fischer T, Beck J, Duyster J, A phase II pilot study of Gleevec (Imatinib mesylate, STI-571) in patients with c-kit positive acute myeloid leukemia (AML). Blood 2002;100:561a
   Web of Science ®Google Scholar
• Kindler T, Breitenbucher F, Marx A, Efficacy and safety of imatinib in adult patients with c-kitpositive acute myeloid leukemia. Blood 2004;103:3644-54
   PubMed Web of Science ®Google Scholar
• Lainey E, Thepot S, Bouteloup C, Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: Delineation of anti-leukemic mechanisms of action. Biochem Pharmacol 2011;82:1457-66
   Google Scholar
• Brandwein JM, Hedley DW, Chow S, A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response. Leukemia 2011;25:945-52
   PubMed Web of Science ®Google Scholar
• Small D, Levenstein M, Kim E, STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 1994;91:459-63
   PubMed Web of Science ®Google Scholar
• Gabbianelli M, Pelosi E, Montesoro E, Multilevel effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/ monocytic precursors. Blood 1995;86:1661-70
   PubMed Web of Science ®Google Scholar
• Sitnicka E, Buza-Vidas N, Larsson S, Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood 2003;102:881-6
   PubMed Web of Science ®Google Scholar
• Carow CE, Levenstein M, Kaufmann SH, Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 1996;87:1089-96
   PubMed Web of Science ®Google Scholar
• Whitman SP, Archer KJ, Feng L, Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001;61:7233-9
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Dugas M, Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-35
   PubMed Web of Science ®Google Scholar
• Chou WC, Hou HA, Liu CY, Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information. Ann Oncol 2011;22:696-704
   PubMed Web of Science ®Google Scholar
• Pratz KW, Sato T, Murphy KM, FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010;115:1425-32
   PubMed Web of Science ®Google Scholar
• Ferrara F, Criscuolo C, Riccardi C, FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype. Am J Hematol 2009;84:532-5
   PubMed Web of Science ®Google Scholar
• Pratz KW, Levis MJ. Bench to bedside targeting of FLT3 in acute leukemia. Curr Drug Targets 2010;11:781-9
   PubMed Web of Science ®Google Scholar
• Knapper S. The clinical development of FLT3 inhibitors in acute myeloid leukemia. Expert Opin Investig Drugs 2011;20:1377-95
   PubMed Web of Science ®Google Scholar
• Weisberg E, Roesel J, Furet P, Antileukemic effects of novel first- and second-generation FLT3 inhibitors: structure-affinity comparison. Genes Cancer 2010;1:1021-32
   PubMedGoogle Scholar
• Fathi AT, Chabner BA. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. Oncologist 2011;16:1162-74
   PubMed Web of Science ®Google Scholar
• Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010;116:5089-102
   PubMed Web of Science ®Google Scholar
• Cortes J, Perl A, Smith C, A phase II open-label, AC220 monotherapy efficacy (ACE) study in patients with acute myeloid leukemia (AML) with FLT3-ITD activated mutations: interim results. Haematologica 2011;96(s2):426
   Google Scholar
• Shiotsu Y, Kiyoi H, Ishikawa Y, KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 2009;114:1607-17
   PubMed Web of Science ®Google Scholar
• Pratz KW, Cortes J, Roboz GJ, A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2009;113:3938-46
   PubMed Web of Science ®Google Scholar
• Fathi AT, Grant S, Karp JE. Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev 2010;36:142-50
   PubMed Web of Science ®Google Scholar
• Leith CP, Kopecky KJ, Godwin J, Acute myeloid leukemia in the elderly: assessment ofmultidrug resistance (MDR1) andvcytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323-9
   PubMed Web of Science ®Google Scholar
• Chauncey TR, Gundacker H, Shadman M, Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. Br J Haematol 2010;148:48-5
   PubMed Web of Science ®Google Scholar
• Kolitz JE, George SL, Marcucci G, P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 2010;116:1413-21
   PubMed Web of Science ®Google Scholar
• Cripe LD, Uno H, Paietta EM, Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 2010;116:4077-85
   PubMed Web of Science ®Google Scholar
• Moccia A, Ghielmini M. Monoclonal antibodies for the treatment of hematologic malignancies: schedule and maintenance therapy. Semin Hematol 2008;45:75-84
   PubMed Web of Science ®Google Scholar
• Stasi R, Evangelista ML, Buccisano F, Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev 2008;34:49-60
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Beck J, Graux C, Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: Results of a multicenter phase 3 study. Blood 2010;115:2586-91
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Sun Z, Litzow MR, Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood 2011;117:5306-13
   PubMed Web of Science ®Google Scholar
• Brunnberg U, Mohr M, Noppeney R, Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. Ann Oncol 2011; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Milligan D, Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011;29:369-7
   PubMed Web of Science ®Google Scholar
• De Propris MS, Raponi S, Diverio D, High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica 2011;96:1548-51
   PubMed Web of Science ®Google Scholar
• Fenton C, Perry CM. Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia. Drugs 2005;65:2405-27
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Brandwein J, Stone R, Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005;23:4110-16
   PubMed Web of Science ®Google Scholar
• Raza A, Jurcic JG, Roboz G, Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymphoma 2009;50:1336-44
   PubMed Web of Science ®Google Scholar
• Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene 2011;30:1009-19
   PubMed Web of Science ®Google Scholar
• Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011;17:313-19
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Guzman M. Acute myeloid leukemia stem cells: seek and destroy. Expert Rev Hematol 2009;2:663-72
   PubMed Web of Science ®Google Scholar
• Peters AH, Schwaller J. Epigenetic mechanisms in acute myeloid leukemia. Prog Drug Res 2011;67:197-219
   PubMedGoogle Scholar
• Hollenbach PW, Nguyen AN, Brady H, A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010;5:e9001
   PubMed Web of Science ®Google Scholar
• Keating GM. Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia. Drugs 2009;69:2501-18
   PubMed Web of Science ®Google Scholar
• Ferrara F, Musto P. Hypomethylating agents for the treatment of acute myeloid leukemia in the elderly: For all, none, or which patients? Cancer 2011;117:3879-81
   PubMed Web of Science ®Google Scholar
• Maurillo L, Venditti A, Spagnoli A, Azacitidine for the treatment of patients with acute myeloid leukemia: Report of 82 patients enrolled in an italian compassionate program. Cancer 2011; Epub ahead of print
   PubMedGoogle Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562-9
   PubMed Web of Science ®Google Scholar
• Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010;28:556-61
   PubMed Web of Science ®Google Scholar
• Ferrara F. Treatment of unfit patients with acute myeloid leukemia: a still open clinical challenge. Clin Lymphoma Myeloma Leuk 2011;11:10-16
   PubMed Web of Science ®Google Scholar
• Walter RB, Appelbaum FR, Tallman MS, Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood 2010;116:2420-8
   PubMed Web of Science ®Google Scholar